Presentation
13 March 2024 Advancing new fluorescent agents that behave similar to Gd-MRI for fluorescence guided neurosurgery
Author Affiliations +
Abstract
Management of intracranial tumors relies heavily on MRI of gadolinium-based contrast agents (Gd-MRI), which plays a central role in diagnosis, surgical planning, intra-surgical guidance, and post-surgical monitoring. Yet, subtotal resection rates remain high, partially due to differences in brain tissue geometry between pre-operative MRI and the surgical field. We reasoned that a nontargeted fluorescent agent that behaves similar to Gd-MRI would provide high tumor contrast, image information familiar to neurosurgeons and alleviate the need to coordinate administration hours before surgery common to other fluorescent agents. We screened several candidate agents in tumor-bearing animals using hyperspectral whole animal fluorescence cryo-tomography and co-registered MRI. This approach enabled evaluation of agent distribution at high resolution in three dimensions and comparison of agents against Gd-MRI. We identified a lead agent that provides high tumor contrast and diagnostic performance within minutes of administration and was highly correlated to the co-registered Gd-MRI volumes. In this presentation, I will review the performance of this agent in small and large animal models.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Scott C. Davis "Advancing new fluorescent agents that behave similar to Gd-MRI for fluorescence guided neurosurgery", Proc. SPIE PC12825, Molecular-Guided Surgery: Molecules, Devices, and Applications X, PC128250B (13 March 2024); https://doi.org/10.1117/12.3023331
Advertisement
Advertisement
KEYWORDS
Fluorescence

Tumors

Neurosurgery

Animals

Magnetic resonance imaging

Lead

Molecules

Back to Top